FIGURE 7.

The effect of dapagliflozin on the MAPK pathway. (A) Venn diagram of dapagliflozin potential targets intersecting with MIRI targets and ferroptosis targets. (B, C) GO functional annotation and KEGG pathway analysis. (D–G) Total cell lysates were immunoblotted for phospho-ERK/ERK, phospho-p38 MAPK/p38 MAPK, phospho-JNK/JNK and quantitative analyses (n = 4, 5 per group). (H, I) The protein levels of phosphor-MEK/MEK were measured by western blotting in vitro (n = 5 per group). (J–L) Phosphorylated ERK/ERK and phosphorylated p38 MAPK/p38 MAPK in vivo experiments were detected by Western blotting and quantitative analyses (n = 6 per group). Data are expressed as mean ± SD; One-way ANOVA followed by Tukey’s correction for post hoc multiple comparisons or Dunnett’s multiple comparison tests; #p < 0.05, ##p < 0.01 vs Control group (in vitro) or Sham group (in vivo); *p < 0.05, **p < 0.01 vs H/R group (in vitro) or I/R group (in vivo).